Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2017 2
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Dose Escalation Study to Assess the Pharmacokinetic Parameters of a Nano-amorphous Oral Sirolimus Formulation in Healthy Volunteers.
Basa-Dénes O, Angi R, Kárpáti B, Jordán T, Ötvös Z, Erdősi N, Ujhelyi A, Ordasi B, Molnár L, McDermott J, Roe C, McKenzie L, Solymosi T, Heltovics G, Glavinas H. Basa-Dénes O, et al. Among authors: ordasi b. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):777-785. doi: 10.1007/s13318-019-00562-y. Eur J Drug Metab Pharmacokinet. 2019. PMID: 31089971 Clinical Trial.
Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
Solymosi T, Ötvös Z, Angi R, Ordasi B, Jordán T, Molnár L, McDermott J, Zann V, Church A, Mair S, Filipcsei G, Heltovics G, Glavinas H. Solymosi T, et al. Among authors: ordasi b. Cancer Chemother Pharmacol. 2017 Oct;80(4):723-728. doi: 10.1007/s00280-017-3406-6. Epub 2017 Aug 3. Cancer Chemother Pharmacol. 2017. PMID: 28776077 Clinical Trial.
Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements.
Solymosi T, Ötvös Z, Angi R, Ordasi B, Jordán T, Semsey S, Molnár L, Ránky S, Filipcsei G, Heltovics G, Glavinas H. Solymosi T, et al. Among authors: ordasi b. Int J Pharm. 2017 Oct 30;532(1):427-434. doi: 10.1016/j.ijpharm.2017.09.031. Epub 2017 Sep 15. Int J Pharm. 2017. PMID: 28919099